港股異動 | 百濟神州(6160.HK)高開8.08% 第二季度產品收入大增120%
格隆匯8月5日丨百濟神州(6160.HK)高開8.08%,報112.4港元,總市值1511億港元。該公司昨日公佈了2022年第二季度美股業績報吿及A股半年度業績快報。截至2022年6月30日的前兩個季度中,公司實現營收6.482億美元。2022年前兩個季度中,百濟神州產品收入達5.661億美元,相比去年同期增長131.3%。在第二季度,產品收入達3.045億美元,較上一年同期增長120%。產品收入的增長主要得益於自主研發產品百悦澤(澤布替尼膠囊)和百澤安(替雷利珠單抗注射液)的銷售增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.